Healthcare Industry News: GammaTile
News Release - October 11, 2022
GT Medical Technologies Announces First Patient Enrolled in GESTALT Trial of GammaTile(R) Therapy for Newly Diagnosed Glioblastoma Brain TumorsThis phase 4 clinical trial evaluates the use of GammaTile Therapy at the time of surgery combined with the standard Stupp protocol for patients with newly diagnosed glioblastomas.
TEMPE, Ariz., Oct. 11, 2022 -- (Healthcare Sales & Marketing Network) -- GT Medical Technologies, Inc. announced the enrollment of the first patient into the GESTALT (GammaTile Enhanced Stupp ALTernative Trial) of GammaTile Surgically Targeted Radiation Therapy (STaRT) for patients with newly diagnosed glioblastomas.
GammaTile Therapy is the only GBM treatment to be FDA cleared in the past decade and one of only 7 FDA-cleared or -approved GBM treatments in the past 50 years. In clinical trials and patient case studies, GammaTile Therapy provides immediate radiation therapy at the time of surgical resection giving patients an effective treatment alternative for newly diagnosed malignant and recurrent brain tumors of all types.
GammaTiles are radiation implants specifically designed for use in the brain. Each resorbable collagen GammaTile is embedded with Cs-131 radiation sources. The neurosurgeon implants GammaTiles in the cavity created by tumor removal. They begin working immediately to combat residual tumor cells.
The GESTALT Clinical Trial will include immediate radiation with GammaTile Therapy followed by the Stupp protocol. The total radiation administered in this clinical trial with GammaTile Therapy and EBRT will be within standard radiation treatment levels.
"Our goal is to demonstrate how starting radiation immediately at the completion of resection and combining it with the Stupp protocol can improve outcomes," said Matt Likens, president and CEO of GT Medical Technologies. "Since GBM is highly proliferative, approximately 50% of patients experience rapid early progression before they can start the Stupp protocol treatment."
"This is an important study built on sound clinical data with the potential to reshape how we approach glioblastoma treatments in the future. We are pleased to offer this study to our patients at M Health Fairview," commented Dr. Clark Chen, the Lyle French Chair and Head of the Department of Neurosurgery, University of Minnesota Medical School. Dr. Chen played an instrumental role in designing the GESTALT Clinical Trial and leads the GESTALT Clinical Team at this site.
About GT Medical Technologies, Inc.
Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies and innovated GammaTile Therapy. FDA-cleared GammaTile Surgically Targeted Radiation Therapy (STaRT) is for all types of newly diagnosed malignant tumors and recurrent brain tumors. Embedded with radiation sources, the resorbable collagen GammaTiles are implanted at the completion of brain tumor removal surgery for immediate treatment—eliminating the standard delay for external beam radiation therapy. With this "one and done" treatment, patients receive radiation therapy as they go about their daily lives, without additional trips to the hospital or clinic. For more information, visit www.gtmedtech.com and follow @GammaTile on Twitter and LinkedIn.
Source: GT Medical Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.